No Data
No Data
Hangzhou Tigermed Consulting Co., Ltd's (SZSE:300347) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?
Abnormal movement hits | CRO concept stocks lead the gains, the Fed's interest rate cuts will be bullish for CXO enterprise customers, and Shanghai issued a document supporting biomedical innovation.
On August 2nd, CRO concept stocks rose in early trading. As of press time, Tigermed (03347.HK) rose 5.67%, reporting 31.7 Hong Kong dollars; WuXi AppTec (02359.HK) rose 4.60%, reporting 33 Hong Kong dollars; Joinn Laboratories (06127.HK) rose 3.85%, reporting 7.56 Hong Kong dollars; Pharmaron (03759.HK) rose 3.80%, reporting 9.84 Hong Kong dollars. Market source: Futubull. On the news front, the Federal Reserve stated that if progress in combating inflation continues as desired, it may announce interest rate cuts at its September meeting. There are
CRO concept stocks rose, with Tigermed (03347) and MediTrust (02158) soaring.
According to Zhitong Finance APP, CRO concept stocks continued to rise in the afternoon. As of press time, Tigermed (03347) rose 7.78% to HKD 29.80, WuXi AppTec (02359) rose 7.54% to HKD 32.10, and iCarbonX (02158) rose 4.40% to HKD 3.56.
Trending Industry Today: WUXI BIO Leads Gains In Pharmaceutical Outsourcing/contract Research Organization(cro Concept) Stocks
Changes in the CRO concept stocks rose in the morning, with Wuxi Apptec's quarterly net income increasing compared to the previous quarter, and Pharmaron achieving a double-digit growth in newly signed order amounts.
On July 31st, CRO concept stocks rose in early trading. As of press time, Wuxi Bio (02269.HK) rose 8.19% to HK$11.36; Wuxi AppTec (02359.HK) rose 8.04% to HK$32.25; Tigermed (03347.HK) rose 7.59% to HK$29.75; Asymchem Laboratories (06821.HK) rose 5.98% to HK$47; Pharmaron (03759.HK) rose 5.97% to HK$9.59. Market information source: Futubull. On the news front, the evening of July 29th.
Hong Kong stock concept tracking | Diabetes prevention and control action plan released, significant progress has been made in the innovative drug research and development of these enterprises (with concept stocks).
According to Frost & Sullivan data, the scale of China's diabetes medication market is expected to reach 167.5 billion yuan by 2030.
No Data